Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 62,900 shares, a drop of 52.7% from the November 30th total of 132,900 shares. Approximately 1.2% of the shares of the stock are sold short. Based on an average trading volume of 211,300 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets dropped their target price on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Monday, December 16th.

Alzamend Neuro Trading Down 3.2 %

Shares of Alzamend Neuro stock traded down $0.04 during trading on Friday, hitting $1.20. The stock had a trading volume of 117,759 shares, compared to its average volume of 477,311. The business has a fifty day moving average of $1.38 and a two-hundred day moving average of $2.42. Alzamend Neuro has a fifty-two week low of $1.06 and a fifty-two week high of $15.06.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.